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BACKGROUND: It has been reported that treatment with uracil-tegafur (UFT) has shown significantly better survival and relapse-free
survival (RFS) than surgery alone. Therefore, we compared UFT with a combination therapy of cyclophosphamide, methotrexate,
and fluorouracil (CMF) in patients who had undergone curative surgery for axillary lymph node-positive breast cancer.
METHODS: A total of 377 node-positive patients with stage I, II, or IIIA disease were registered from September 1996 through July 2000
and were randomly assigned to either 6 cycles of CMF or 2 years of UFT. In both arms, tamoxifen (TAM) was concurrently
administered for 2 years. The primary end point in this study was the non-inferiority of UFT to CMF.
RESULTS: No statistically significant difference between the two groups was observed with regard to the 5-year RFS rate (72.2% in the
UFT and 76.3% in the CMF). Adverse event profiles differed between the two groups, with a significantly lower incidence of
leukopenia and anaemia in the UFT group, as well as anorexia, nausea/vomiting, stomatitis, and alopecia, which have implications for
quality of life.
CONCLUSION: UFT administered in combination with TAM holds promise in the treatment of lymph node-positive early breast cancer.
On stratified analysis, the recurrence rate in the UFT group was found to be better in oestrogen receptor (ER)-positive patients.
Tegafur-based treatment should be evaluated by a prospective randomised trial conducted in ER-positive patients.
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The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
conducts a meta-analysis of randomised studies of post-operative
adjuvant therapy for breast cancer every 5 years (EBCTCG, 2005).
They reported that polychemotherapy (cyclophosphamide (CPA),
methotrexate (MTX), fluorouracil (5-FU) ((CMF))-based; anthra-
cycline-based; or other types of polychemotherapy) was associated
with a decrease in the odds ratio of disease-free survival and an
overall improvement in survival compared with no chemotherapy
(EBCTCG, 1998).
The relatively recent addition of taxanes to anthracycline-based
chemotherapy has markedly improved outcomes of post-operative
chemotherapy for node-positive breast cancer (Ferguson et al, 2009).
Furthermore, concomitant chemotherapy with trastuzumab, an anti-
human epidermal growth factor receptor 2 (HER2) antibody, has been
reported to substantially improve outcomes in resected HER2-positive
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and regimens should be done in careful consideration of anticipated
risks, expected benefits, and estimated costs.
Associated with fewer adverse events such as cardiotoxicity and
bone marrow suppression compared with anthracycline- or
taxane-based regimens, CMF therapy remains widely used as a
therapeutic option. Furthermore, if therapeutic drugs could be
administered orally instead of being intravenously infused,
patients with breast cancer would benefit greatly because oral
formulations are more convenient, are associated with fewer
adverse events such as alopecia, and have higher compliance.
With regard to monotherapy regimens, oral fluoropyrimidines
such as uracil-tegafur (UFT) (Taguchi, 1997), which are suitable
for ambulatory-based treatment, have been used in Japan since the
1980s. Tashiro et al (1994) reported a response rate for UFT in
patients with recurrent breast cancer of 39%, which is comparable
with the 36% reported for CMF in patients with advanced or
recurrent breast cancer in Japan (Nomura et al, 1994), as well as
markedly lower toxicity for UFT than CMF. These results suggest
that UFT likely prevents relapse as effectively as CMF in post-
operative adjuvant therapy for breast cancer, but with a lower
severity of adverse events.
Furthermore, in the adjuvant setting, treatment with UFT has
shown significantly better survival and relapse-free survival (RFS)
than surgery alone in prospective randomised clinical trials in
breast cancer (Kasumi et al, 2003; Noguchi et al, 2005).
Here, we conducted a randomised study to compare UFT with
CMF in patients with axillary lymph node-positive stage I, II, or
IIIA breast cancer.
PATIENTS AND METHODS
Eligibility criteria
Eligibility criteria included (1) TNM stage I, II, or IIIA; (2)
involvement of 1–9 axillary lymph nodes; (3) curative surgery; (4)
age 20–65 years; (5) body weight X40kg; (6) normal haemato-
logical parameters as well as adequate hepatic and renal function;
and (7) written informed consent. Patients with bilateral breast
cancer, male breast cancer, inflammatory breast cancer, and
double cancers were excluded, as were pregnant or lactating
women with breast cancer. Patients were eligible regardless of their
oestrogen receptor (ER) status. The cutoff level of ER was
13fmolmg
 1 soluble fraction in terms of enzyme immunoassay.
Consecutive patients who met all of the eligibility criteria and
received treatment as specified were included in the analysis.
Study design
The study scheme is shown in Figure 1. The UFT (Taiho
Pharmaceuticals Co. Ltd., Tokyo, Japan) group received tamoxifen
(TAM, AstraZeneca K.K., Osaka, Japan) (20mgday
 1) in combi-
nation with UFT (270mgm
 2day
 1) for 2 years. The CMF group
received TAM (20mgday
 1) for 2 years in combination with
6 cycles of CPA (Shionogi & Co. Ltd., Osaka, Japan) (65mgm
 2:
days 1–14), MTX (Wyeth K.K., Tokyo, Japan) (40mgm
 2: days 1
and 8), and 5-FU (Kyowa Hakko Kirin Co. Ltd., Tokyo, Japan)
(500mgm
 2: days 1 and 8), with the cycle repeated every 4 weeks.
Laboratory tests and observation of signs and symptoms were
carried out every month in the UFT group for the first 6 months
and thereafter at intervals of 3 months for the remainder of the
2-year treatment period, and on days 1, 8, and 15 of each cycle in
the CMF group. Adverse events were assessed according to the
grade classification of the Japan Society of Clinical Oncology,
which are equivalent to the World Health Organization in all
substantial aspects. Eligibility of subjects, cases of relapse, and
deaths were clinically reviewed by the Data Review Committee.
The study protocol was approved by the institutional review board
of each participating institution. All procedures were carried out in
accordance with the Declaration of Helsinki.
Statistical considerations
The primary end point in this study was the non-inferiority of
the UFT group to the CMF group, as measured by the RFS rate.
The secondary end point was superiority with regard to a lower
Central randomisation
Minimisation: T factor (T1, T2, T3), n factor (1–3, 4–6, 7–9)
Age (–49, 50– years), ER (+, –, unknown)
Follow-up: every  3 months for 2 years and every 6 months thereafter
Patient enrolment: September 1996–July 2000
Mastectomy
CMF+TAM
CPA 65 mg m–2 day–1 (po)
2Y 0
Surg
↑↑ ↑↑ ↑↑ ↑↑ ↑↑
20W 16W 12W 8W 4W 2W
d 14
1W
d 8
MTX 40 mg m–2 (i.v.)
5-FU 500 mg m–2 (i.v.)
↑
d 1
MTX
5-FU
↑
1 course (4 weeks)
TAM 20 mg per body per day (po) TAM 20 mg per body per day (po)
UFT 270 mg m–2 day–1 (po)
2Y 0
Surg
UFT+TAM
Figure 1 Study design. ER, oestrogen receptor; CMF, cyclophosphamide–methotrexate–fluorouracil; TAM, tamoxifen; UFT, uracil-tegafur; W, week; Y,
year; Surg, surgery; po, per os; CPA, cyclophosphamide; d, day; MTX, methotrexate; 5-FU, fluorouracil; i.v., intravenous.
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reported a 9.4±1.4% difference in 5-year recurrence-free survival
rate in node-positive patients between the CMF therapy and
control groups (EBCTCG, 1992), we adopted an approximate value
of D10% to demonstrate clinical non-inferiority. We estimated a
5-year RFS rate of 70% in both the UFT and the CMF groups. As
D10% corresponds to a hazard ratio (HR) of 1.43, demonstration
of non-inferiority required the upper limit of the 90% confidence
interval for the HR of the UFT group relative to the CMF group to
be p1.43. Demonstration of non-inferiority at a significance level
of 0.05 (one-sided) with a power of 80% in turn required a sample
size of 648 subjects. Therefore, we selected a sample size of 680
subjects, in consideration of the likely number of ineligible
subjects and subjects not treated as specified.
Distribution of background factors and the incidence of adverse
events were analysed using the w
2 test and Mann–Whitney U-test,
respectively. Relapse-free survival time was defined as the period
from the day of surgery to the day of final confirmation of a
relapse-free status or to the first confirmation of relapse. For
subjects who died of any cause other than relapse of the underlying
disease, RFS time was defined as the period from the day of
surgery to the day of death, with death considered as an event.
Survival time was defined as the period from the day of surgery to
the day of final confirmation of survival or to the confirmation of
death from any cause.
Analyses in this study were performed on evaluable patients.
Analyses were carried out using SAS software (version 6.12, SAS
Institute, Cary, NC, USA), with the PHREG procedure used to
estimate HR. In accordance with changes introduced by the ICH
International Conference on Harmonization E9 (1998), the upper
limit of the confidence intervals was changed to 95%. Both RFS
and survival were estimated using the Kaplan–Meier method and
analysed by the log-rank test. A P-value o0.05 was considered to
indicate a statistically significant difference.
RESULTS
Enrolment and patient characteristics
Patient characteristics are shown in Table 1. Recruitment began in
September 1996 at 100 participating clinical sites in Japan. The
recruitment period was extended in June 1988 from the originally
planned 2 years to 4 years because the target number of subjects
had not been reached. Despite this, only half the target sample size
was achieved because of slow accrual and, as a result, recruitment
was terminated in July 2000 with 377 enrolled patients. Among the
377 patients, 188 were randomised to the UFT group, with 3
excluded as being ineligible and 8 for protocol violations, leaving
177 patients for inclusion in the analysis. For the CMF group, 189
patients were randomised, with 7 excluded as being ineligible and
9 because of protocol violations, leaving 173 patients for analysis.
No marked bias was observed in age distribution, hormone
receptor status, number of involved axillary lymph nodes, or
histological type. The frequency of ER-positive cases in the UFT
and CMF groups was the same (51.4%).
Efficacy
Both RFS and survival curves are shown in Figure 2. The 5-year
RFS rates in the UFT and CMF groups were 72.2 and 76.3%,
respectively, with no statistically significant difference between
them (log-rank test, P¼0.46). The HR for the UFT group
relative to the CMF group in terms of RFS rate was 1.18 (95%
CI: 0.77–1.80). Five-year survival rates in the UFT and CMF
groups were 87.0 and 88.4%, respectively, showing no statistically
significant difference between them, and the HR was 1.15 (log-rank
test, P¼0.66). Subset analysis showed that there were non-
significant tendencies of interaction between RFS and age, number
of involved lymph nodes and ER status (Figure 3).
The number of cases of relapse and the distribution of sites are
shown in Table 2. There were 45 (25.4%) and 39 (22.5%) cases of
relapse in the UFT and CMF groups, respectively. The most
common initial site of relapse was soft tissue, followed by bone and
visceral organs in both the groups. In addition, neither secondary
breast cancer nor other malignancies were observed in both the
groups. No difference in the number of cases or distribution of
sites was observed between the two groups.
Safety
Adverse events are shown in Table 3. Adverse events were reported
in 88.1% (156 out of 177) of patients receiving UFT and in 98.8%
(171 out of 173) of those receiving CMF, showing a significantly
lower incidence in the UFT group (Po0.05). The incidence of
leukopenia as well as haemoglobin, anorexia, nausea/vomiting,
stomatitis, and alopecia was significantly higher in the CMF group,
whereas that of liver dysfunction was significantly higher in the
UFT group.
Dose and concomitant medications
The mean total dose of UFT was 75.2% of the target dose, whereas
the mean total doses of CPA, MTX, and 5-FU were 85.8, 83.3, and
83.7% of the target dose, respectively. The mean total dose of TAM
in the UFT and CMF groups was 85.7 and 86.7% of the target dose,
respectively, and thus was not different between the two groups.
Table 1 Patient characteristics
CMF UFT
No. of enrolled patients 189 188
No. of eligible patients 182 185
No. of evaluable patients 173 177
Age (mean±s.d.) 51.0±7.7 51.7±7.8
o50years 88 88
X50years 85 89
Body surface area (m
2, mean±s.d.) 1.47±0.11 1.48±0.11
T
T1 36 31
T2 122 132
T3 15 14
n
1–3 135 138
4–6 26 25
7–9 12 14
Hormone receptor status
ER( ) and PgR( )5 2 5 3
Others 121 124
ER( )7 3 7 2
ER(+) 89 91
Unknown 11 14
PgR( )7 3 7 3
PgR(+) 78 78
Unknown 8 6
Histological pattern
Invasive ductal ca. 165 160
Lobular ca. 5 7
Others 3 10
ca.¼carcinoma; CMF¼cyclophosphamide–methotrexate–fluorouracil; ER¼oestrogen
receptor; PgR¼progesterone receptor; UFT¼uracil-tegafur.
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10 subjects (5.8%) in the CMF group, but not in any subjects in the
UFT group. We used 5-hydroxytryptamine 3 (5-HT3) antagonists
in 80 subjects (46.2%) in the CMF group, but in only 1 subject
(0.6%) in the UFT group. The use of both G-CSFs and anti-emetics
was statistically significantly less frequent in the UFT group
(both P¼0.001).
CONCLUSION
In this study, we found no statistically significant difference in RFS
among patients who had undergone curative surgery for axillary
lymph node-positive breast cancer between those receiving UFT
and CMF, at 72.2 vs 76.3%, respectively. In addition, the UFT
All patients
Age, years
< 50
Nodal status
n1–3
n4–9
ER
Negative
Positive
PgR
Negative
Positive
ER/PgR
Both negative
ER-positive or PgR-positive
1.18 (0.80 – 1.80)
1.80 (0.96 – 3.41)
0.81 (0.45 – 1.46)
1.50 (0.89 – 2.56)
0.66 (0.31 – 1.37)
1.63 (0.90 – 2.98)
0.73 (0.38 – 1.39)
1.24 (0.69 – 2.21)
0.72 (0.35 – 1.50)
1.30 (0.69 – 2.47)
0.79 (0.42 – 1.50)
Hazard ratio
(95% Cl)
350
160
190
273
77
145
180
146
156
105
206
No. of
patients
0.07
0.07
0.26
0.28
0.07
Test for
interaction
Hazard ratio and 95% Cl
Risk reduction
In favour of UFT
> 50
In favour of CMF
0.0 3.5 4.0 0.5 1.0 1.5 2.0 2.5 3.0
Figure 3 Relapse-free survival by age, number of involved nodes and ER, PgR, and ER/PgR status.
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Figure 2 Relapse-free and overall survival. (A) Relapse-free survival; (B)
overall survival. CMF, cyclophosphamide–methotrexate–fluorouracil; UFT,
uracil-tegafur; CI, confidence interval.
Table 2 Sites of relapse
CMF UFT
No. of evaluable patients 173 177
No. of relapse cases 39 (22.5%) 45 (25.4%)
Soft tissue 18 (10.4%) 23 (13.0%)
Skin and subcutaneous tissues 9 (5.2%) 12 (6.8%)
Lymph node 10 (5.8%) 12 (6.8%)
Contralateral breast 1 (0.6%)
Bone 15 (8.7%) 12 (6.8%)
Visceral organs 14 (8.1%) 19 (10.7%)
Lung and pleura 8 (4.6%) 12 (6.8%)
Liver 7 (4.0%) 7 (4.0%)
Brain 2 (1.2%) 2 (1.1%)
Others 1 (0.6%)
CMF¼cyclophosphamide–methotrexate–fluorouracil; UFT¼uracil-tegafur.
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with the CMF group (Po0.05). Moreover, G-CSFs were used by 0
and 5.8% of subjects who received UFT and CMF therapies,
respectively, and 5-HT3 antagonists by 0.6 and 46.2%, respectively.
One particular limitation of this study warrants mention. Owing
to its small sample size, this study did not have sufficient statistical
power to demonstrate the non-inferiority of UFT to CMF.
However, the HRs for RFS and survival calculated over 5 years
were 1.18 and 1.15, respectively, which are consistent with the RFS
and survival curves. Furthermore, the number of cases was
sufficient enough to verify significant differences between the
UFT and CMF groups with regard to adverse events. The UFT
group had a significantly lower incidence of adverse events. These
differences indicate the possibility of using UFT as a treatment
option in place of CMF.
Similar findings were recently reported in a randomised study of
stage I–IIIA node-negative, pathologically high-risk breast cancer,
which compared a 2-year administration of UFT with 6 cycles of
CMF (Watanabe et al, 2009). Results indicated that the efficacy of
UFT as an adjuvant treatment was comparable with that of CMF.
On the other hand, Cancer and Leukemia Group B (CALGB)
reported that a 4.5-month administration of capecitabine was
inferior to CMF/AC (doxorubicin (ADM)þCPA) in elderly breast
cancer patients (Muss et al, 2009). This disagreement among results,
including those of this study, might be partly explained by the
difference in the duration of treatment with oral fluoropyrimidines.
An additional finding of our study was that subset analysis
indicated a tendency of interaction among age, number of involved
lymph nodes, or ER status and RFS, suggesting that these subsets
may affect therapeutic effect. Among these three subsets, it is
unclear why UFT was superior to CMF in patients with four or more
metastatic axillary lymph nodes. With regard to age in pre-
menopausal women, relapse prevention by CMF is mainly attribu-
table to its chemical oophorectomy effect, but in post-menopausal
women primarily to other mechanisms, such as cytotoxic effects.
In contrast, UFT is reported to have anti-angiogenic effects in
addition to its cytotoxic effects based on the evaluation in BALB/c
mouse models (Yonekura et al, 1999; Munoz et al, 2006). These
findings may explain the higher efficacy of UFT than CMF in
patients aged X50 years. With regard to ER status, our findings
support previous findings that concurrent treatment with UFT and
TAM yields better outcomes in patients with ER-positive
breast cancer than does monotherapy with TAM (Noguchi et al,
2005). Given the finding by Albain (1989) that the CAF–TAM
combination treatment is more effective in sequential than in
concurrent administration, combination treatment with anthracy-
cline-based infusional therapy with TAM is believed to have
equivalent or lower efficacy when administered concurrently
than sequentially. However, the validity of the concurrent
approach in vitro has been demonstrated (Kurebayashi et al,
2007). The combination of 4-hydroxy-TAM (4OHT) and 5-FU had
an additive effect in inhibiting the proliferation of ER-a-positive
cells, whereas that of 4OHT and ADM worked antagonistically.
With regard to changes in gene expression for susceptibility or
tolerance to TAM, 5-FU, or ADM, 5-FU did not change the
expression level of TAM-related genes, whereas 4OHT significantly
inhibited thymidylase synthase, which is a key enzyme in the anti-
tumour activity of 5-FU, and thereby enhanced the anti-tumour
effect of 5-FU. In contrast, ADM did not change gene expression
for TAM susceptibility, but did increase the expression of some
genes for TAM tolerance. The authors considered this to indicate
the fact that ADM in combination with 4OHT may exert a rather
negative anti-tumour effect. Furthermore, anthracyclines are
reportedly less effective against HER2-negative than HER2-positive
breast cancers (Gennari et al, 2008), whereas the relapse-
preventative effect of UFT is not affected by HER2 status (Toi
et al, 2007).
The Consensus Guideline (Goldhirsch et al, 2007) established at
the St Gallen Conference states that no therapeutic modality has
been established for HER2-negative and hormone receptor-positive
intermediate-risk breast cancer. The question of whether post-
operative endocrine therapy alone is sufficient in these patients or
should be supplemented with chemotherapy remains unanswered.
As mentioned above, as UFT can prevent ER-positive breast cancer
from recurring when combined with hormone therapy, regardless of
HER2 status, it may provide a useful therapeutic option for patients
with intermediate-risk breast cancer.
In conclusion, these findings suggest that UFT may hold
promise as a treatment for the prevention of relapse of node-
positive early breast cancer. Tegafur-based treatment should
be evaluated by a prospective randomised trial conducted in
ER-positive patients.
Table 3 Adverse events
CMF (n¼173) UFT (n¼177)
Grade Grade
Unknown 1 2 3 4 Incidence (%) Unknown 1 2 3 4 Incidence (%) P-value
a
Leukopenia 87 50 6 82.7 49 10 33.3 Po0.001
Thrombocytopenia 21 2 13.3 35 2 20.9
Haemoglobin 52 2 1 31.8 11 2 7.3 Po0.001
AST 45 11 32.4 45 16 1 35.0
ALT 47 16 36.4 51 16 2 39.0
Hepaplastin decrease 1 0.6 9 5.1 Po0.05
Total bilirubin 3 1.7 43 3 1 26.6 Po0.001
ALP 4 2.3 25 14.1 Po0.001
BUN 2 1 1.7 10 5.6
Creatinine — 1 0.6
Anorexia 62 18 6 49.7 1 34 4 1 22.6 Po0.001
Nausea/vomiting 84 28 8 69.4 1 32 6 1 22.6 Po0.001
Diarrhoea 1 8 5.2 2 11 7.3
Stomatitis 17 3 11.6 2 3 2.8 P¼0.002
Pigmentation 7 2 5.2 12 4 9.0
Numbness in fingers 1 0.6 1 0.6
Alopecia 57 11 9.3 4 2.3 Po0.001
aw
2 test. ALP¼alkaline phosphatase; ALT¼alanine aminotransferase; AST¼aspartate aminotransferase; BUN¼blood urea nitrogen; CMF¼cyclophosphamide–
methotrexate–fluorouracil; UFT¼uracil-tegafur.
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